{"id":385,"date":"2019-07-11T21:02:25","date_gmt":"2019-07-11T21:02:25","guid":{"rendered":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/?page_id=385"},"modified":"2026-06-01T10:07:36","modified_gmt":"2026-06-01T15:07:36","slug":"awarded-grants","status":"publish","type":"page","link":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/","title":{"rendered":"Awarded Grants"},"content":{"rendered":"

[vc_row][vc_column width=”2\/3″][vc_column_text css=””]2026<\/strong><\/p>\n

Development of first-in-class AAK1 Protacs for Ovarian Cancer.<\/strong>
\nR01, 6\/26 \u2013 2\/31, Total Direct Costs: $963,795
\nLingtao Jin, PhD<\/p>\n

Targeting Mucin-Type O-Glycosylation for EGFR mutant non-small cell lung cancer.<\/strong>
\nR01, 4\/26 \u2013 3\/31, Total Direct Costs: $1,036,970
\nLingtao Jin, PhD<\/p>\n

2025<\/strong><\/p>\n

Targeting Mutant ER-Mediated Enhancer Condensates to Overcome Persistent ER Activity in Endocrine-Resistant, Metastatic Breast Cancer
\n<\/strong>CPRIT, 11\/25 \u2013 11\/28, Total Direct Costs: $899,991
\nZhijie Liu, PhD<\/p>\n

Charting cellular attraction-based interactome with Multivalent Adhesive Probe AFM (MAPA)<\/strong>
\nR61, 09\/2025 \u2013 08\/2028, Total Direct Costs: $134,550
\nPawel A. Osmulski, PhD & Marie E. Gaczynska, PhD<\/p>\n

Targeting METTL3 to overcome drug resistance in metastatic clear cell renal cell carcinoma\u00a0<\/strong>
\nDOD, 09\/2025 \u2013 08\/31\/29, Total Direct Costs: $248,960
\nKarthigayan Shanmugasundaram, PhD<\/p>\n

Equipment-Only Grant For: 10X Genomics Xenium Analyzer<\/strong>
\nS10, 7\/15\/2025 \u2013 7\/14\/2026, Total Direct Cost: $365,000
\nZhao Lai, PhD<\/p>\n

Selisistat as an anti-prostate cancer agent for treatment of prostate cancer
\n<\/strong>DOD, 06\/01\/25 \u2013 05\/31\/28, Total Direct Costs: $400,000
\nA. Pratap Kumar<\/p>\n

Organelle Communication During Transition From Fatty Liver to Hepatocellular Carcinoma<\/strong>
\nCPRIT, 2025 \u2013 2028, Total Direct Costs: $900,000
\nMasahiro Morita, PhD<\/p>\n

2024<\/strong><\/p>\n

TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs<\/strong>
\nCPRIT, 2024 \u2013 2029, Total Direct Costs: $900,000
\nMingjiang Xu, PhD & Ying Li, PhD
\n<\/strong><\/p>\n

Therapeutic Value and Mechanistic Action of PSPC1 in AML<\/strong>
\nRO1, 2024 \u2013 2029, Total Direct Costs: $1,020,715
\nMingjiang Xu, PhD<\/p>\n

Critical Roles of RNA m5C-MBD6-H2AK119ub Deubiquitylation Axis in TET2-Mediated HSC Regulation<\/strong>
\nRO1, 2024 \u2013 2028, Total Direct Costs: $932,088
\nMingjiang Xu, PhD<\/p>\n

AXL-STAT3-PD1 Targeting of Tumor Immune Microenvironments\u00a0<\/strong>
\nV Foundation, 2024 \u2013 2027, Total Direct Costs: $800,000
\nJosephine Taverna, PhD<\/p>\n

The Role of Tumor-Macrophage Hybrid Cells in Prostate Cancer Metastasis<\/strong>
\nU01, 2024 \u2013 2028, Total Direct Costs: $2,055,380
\nTim Huang, PhD<\/p>\n

Identification of APE2 Nuclease Inhibitors\u00a0<\/strong>
\nWilliam and Ella Owens Medical Research Foundation, 2024 \u2013 2026, Total Direct Costs: $200,000
\nSang Lee, PhD<\/p>\n

Mechanisms of Enhancer Dynamics and Assembly in Gene Regulation<\/strong>
\nR35 2024 \u2013 2029, Total Direct Costs: $1,250,000
\nZhijie Liu, PhD<\/p>\n

Development of a New Class of EZH2 Inhibitors in Era-negative Breast Cancer<\/strong>
\nR21 2024 \u2013 2026, Total Direct Costs: $257,125
\nKexin Xu, PhD<\/p>\n

Function of the METTL3-NUP93 Complex-Mediated Nuclear Export of m6A-modified mRNAs in Castration-Resistant Prostate Cancer<\/strong>
\nR01 2024 \u2013 2029, Total Direct Costs: $1,536,138
\nKexin Xu, PhD<\/p>\n

The Role of EWSR1-FlI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma<\/strong>
\nCancer Prevention and Research Institute of Texas, 2024 \u2013 2028, Total Direct Costs: $1,330,000
\nKatasumi Kitagawa, PhD<\/p>\n

Activation of Drug and Biologic Conjugates by Click Chemistry and their Tumor-Selective Targeting for Prostate Cancer Suppression<\/strong>
\nR21, 2024 \u2013 2026, Total Direct Costs: $140,250
\nBandana Chatterjee, PhD<\/p>\n

Novel Human Oguchi Disease Mechanism\u00a0<\/strong>
\nRetina Research Foundation, 2024, Total Direct Costs: $45,000
\nChing-Kang Chen, PhD<\/p>\n

Deciphering RNA Splicing Control of Lipid Metabolism and Alcoholic Liver Injury\u00a0<\/strong>
\nAlcohol Research Programs, 2024 \u2013 2029, Total Direct Costs: $1,668,520
\nMengwei Zang, PhD<\/p>\n

2023<\/strong><\/p>\n

Bruker Atomic Force Microscope NanoWizard 5<\/strong>
\nS10, 2023 \u2013 2024, Total Direct Costs: $590,043
\nPawel Osmulski PhD<\/p>\n

The Role and Mechanism of RNA m6A Modification in the Pathogenesis and Drug-Resistance of Prostate Cancer<\/strong>
\nNCI, 2023, Total Direct Costs: $1,234,879
\nJihoon Lee, PhD<\/p>\n

Novel Proteasome-Activating Compounds for Treatment of Alzheimer’s Disease<\/strong>
\nOwens Medical Research Foundation, 2023, Total Direct Costs: $200,000
\nMaria Gaczynska, PhD, Pawel Osmulski, PhD<\/p>\n

The SNAI2-RUNX2 Signaling Axis is a Novel Driver of Osteosarcoma Initiation, Growth and Therapy Resistance<\/strong>
\nAmerican Cancer Society, 2023, Total Direct Costs: $167,000
\nMyron Ignatius, PhD<\/p>\n

Targeting SNAI2 Resistance Mechanisms in Pediatric RAS Mutant Rhabdomyosarcoma\u00a0<\/strong>
\nWilliam and Ella Owens Medical Research Foundation, 2023
\nMyron Ignatius, PhD<\/p>\n

Toward Clinical Trial:AXL-STAT3 Targeting of Lung Tumor Microenvironments<\/strong>
\nNIH\/NCI, 2023, Total Direct Costs: $1,627,759
\nJosephine Taverna, PhD<\/p>\n

Tvardi Pilot Grant (Taverna)<\/strong>
\nTvardi Pilot Grant, 2023, Total Direct Costs: $50,000
\nJosephine Taverna, PhD<\/p>\n

Repair of DNA ends with Adducts\u00a0<\/strong>
\nNIH\/NIGMS 2023, Total Direct Costs: $800,000
\nSang Eun Lee, PhD<\/p>\n

Roles of T-box Transcriptional Regulators in the Development of RGC Subtypes<\/strong>
\nUTHSC-Houston, 2023, Total Direct Costs: $98,090
\nChing-Kang Jason Chen, PhD<\/p>\n

2022<\/strong><\/p>\n

The Role of Transducin – and Melanopsin-Independent Phototransduction in Postnatal Retinal Development<\/strong>
\nNIH 2022, Total Direct Costs: $1,125,000
\nChing-Kang Jason Chen, PhD<\/p>\n

The Function of Wide-Field Amacrine Cells in Mammalian Retina\u00a0<\/strong>
\nNIH 2022, Total Direct Costs: $1,250,000
\nChing-Kang Jason Chen, PhD<\/p>\n

Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San Antonio\u00a0<\/strong>
\nNIH NCI R50 2022, Total Direct Costs: $617,000
\nZhao Lai, PhD<\/p>\n

UT System Rising STARs\u00a0<\/strong>
\n2022, Total Direct Costs: $250,000
\nLingtao Jin, PhD<\/p>\n

METTL3 as a Therapeutic Target in Uterine Fibroids<\/strong>
\n2022, Total Direct Costs: $50,000
\nKarthigayan Shanmugasundaram, PhD<\/p>\n

Improving Therapeutic Approaches for RAS-driven Rhabdomyosarcoma<\/strong>
\nNIH-NCI- R37CA262657, 2022, Total Direct Costs: $1,143,749
\nPI-Angelina Vaseva, PhD<\/p>\n

Organelle Communication During Transition from Fatty Liver to Hepatocellular Carcinoma<\/strong>
\nCPRIT, 2022, Total Direct Costs: $1,050,000
\nMasahiro Morita, Ph.D<\/p>\n

Targeting tumor-immune microenvironment to improve durvalumab efficacy in small cell lung cancer<\/strong>
\nLung Cancer Research Foundation\/AstraZeneca, 2022, Total Direct Costs: $180,000
\nLingtao Jin, Ph.D<\/p>\n

Novel small molecule inhibitors for the treatment of rhabdomyosarcoma<\/strong>
\nNIH, 2022, Total Direct Costs: $150,000
\nRaushan Kurmasheva, PhD<\/p>\n

2021<\/strong><\/p>\n

AXL-STAT3 Targeting of Lunch Tumor Microenvironments in Patient Derived Mouse Models<\/strong>
\nThe Max & Minnie Tomerlin Voelcker Fund, Total Direct Costs: $350,000
\nJosephine Taverna, PhD<\/p>\n

The role of lipid metabolism in dendritic cell-mediated anti-tumor immunity<\/strong>
\nAmerican Lung Association, 2021, Total Direct Costs: $150,000
\nLingtao Jin, PhD<\/p>\n

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer\u00a0<\/strong>
\nNIH\/NCI, 2021, Total Direct Costs: $3,502,418
\nHoughton, Ph.D., Kurmasheva, PhD<\/p>\n

Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors\u00a0<\/strong>
\nNIH\/NCI, 2021, Total Direct Costs: $1,904,289
\nHoughton, PhD, Kurmasheva, PhD<\/p>\n

Illumina NovaSeq 6000 Sequencing System<\/strong>
\nNIH, 2021, Total Direct Costs: $600,000
\nZhao Lai, PhD<\/p>\n

The functional role of MAST1 in mediating a-synucleinopathies and related dementia<\/strong>
\nNIH\/NCI\/NIA, 2021, Total Direct Costs: $350,000
\nLingtao Jin, PhD<\/p>\n

Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization<\/strong>
\nNIH-NCI R01CA260729, 2021, Total Direct Costs: $933,750
\nMingjiang Xu, PhD<\/p>\n

METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs<\/strong>
\nNIH, 2021, Total Direct Costs: $1,075,000
\nKexin Xu, PhD<\/p>\n

Targeting AXL-JAK1 in tumor immune microenvironments of lung adenocarcinoma<\/strong>
\nVoelcker Fund Young Investigator Award, 2021, $350,000
\nJosephine Taverna, MD<\/p>\n

Leveraging oxysterol sulfotransferase in prostate cancer progression\u00a0<\/strong>
\nDepartment of Defense, 2021, Total Direct Costs: $1,161,253
\nBandana Chatterjee, PhD<\/p>\n

PAI-1-mediadted early-onset endometrial cancer<\/strong>
\nNIH, 2021, Total Direct Costs: $2,692,120
\nTim H.M. Huang, PhD, Nameer B. Kirma, PhD<\/p>\n

2020<\/strong><\/p>\n

Calming the cytokine storm with proteasome-targeting immunomodulators\u00a0<\/strong>
\nSan Antonio Medical Foundation, 2020, $93,000
\nMaria Gaczynska, PhD<\/p>\n

Enhancing Cytarabine Response Through SAMHD1 Inhibition\u00a0<\/strong>
\nCancer Prevention and Research Institute of Texas (CPRIT), 2020,\u00a0Total Direct Costs: $ 1,138,728
\nIvanov, PhD, Kurmasheva, PhD<\/p>\n

Mammalian Target of Rapamycin (MTOR) signaling and the suprachiasmatic circadian clock<\/strong>
\nNIH, 2020, $27,778
\nVictor Jin, PhD<\/p>\n

Omics analysis of three-dimensional transcription regulation<\/strong>
\nNIH, 2020, $144,184
\nVictor Jin, PhD<\/p>\n

Role of RTEL1 in Microhomology-Mediated end joining\u00a0<\/strong>
\nNIH, 2020, $150,000
\nSang-Eun Lee, PhD<\/p>\n

Targeting Microhomology-Mediated end joining to sensitize recombination deficient cancer cells<\/strong>
\nOwens Foundation, 2020, $80,000
\nSang-Eun Lee, PhD<\/p>\n

Novel Coregulators of estrogen receptor in enhancer-regulated transcription\u00a0<\/strong>
\nNIH, 2020, $1,250,000
\nZhijie Liu, PhD<\/p>\n

Targeting a non-canonical role of YAP\/TEAD for\u00a0\u00a0<\/strong>
\nMary Kay Foundation, 2020, $100,000
\nZhijie Liu, PhD<\/p>\n

Targeting AXL-JAK1 in tumors and immune ecosystems of lung cancer\u00a0<\/b>
\nVoelcker Foundation, 2020, $100,000
\nJosephine Taverna, MD<\/p>\n

Role of HOTTIP IncRNA in leukemogenesis<\/strong>
\nCancer Prevention & Research Institute of Texas, 2020, $900,000
\nMingjiang Xu, PhD<\/p>\n

2019<\/strong><\/p>\n

Endometriosis diagnosis by communicome gene single-cell expression<\/strong>
\nPresidential Translational and Entrepreneurial Research Fund, 2019, $25,000
\nNameer B. Kirma, PhD<\/p>\n

Berberine in the prevention of biochemical recurrence<\/strong>
\nCancer Prevention & Research Institute of Texas, 2019, $900,000
\nA. Pratap Kumar, PhD<\/p>\n

Potentiation of Gemcitabine activity in pancreatic cancer<\/strong>
\nWilliam & Ella Owens Foundation of America, 2019, $96,810
\nA. Pratap Kumar, PhD<\/p>\n

Epigenetic-mediated alternative splicing in SF3B1-mutated CLL patients<\/strong>
\nWilliam & Ella Owens Foundation of America, 2019, $100,000
\nVictor Jin, PhD<\/p>\n

PARP Inhibition: Elucidating Mechanisms of Resistance to Improve Therapy\u00a0<\/strong>
\nUT Health San Antonio Mays Cancer Center Pilot Award, 2019,Total Direct Costs: $50,000
\nKurmasheva, PhD<\/p>\n

PARP1\/MGMT Interaction as a Potential Target for Cancer<\/strong>
\nChildhood Cancer Research Fund (CCRF), 2019,\u00a0Total Direct Costs: $100,000
\nKurmasheva, PhD<\/p>\n

Development of novel anti-cancer compounds targeting dimerization of proteasome with its regulatory modules<\/strong>
\nWilliam & Ella Owens Foundation of America, 2019, $99,177
\nMaria Gaczynska, PhD, Pawel Osmulski, PhD<\/p>\n

Precision targeting of MED12-mutant CLL with Notch inhibitors<\/strong>
\nThomas Boyer, PhD<\/p>\n

Combating Protein-misfolding Diseases<\/strong>
\nWilliam & Ella Owens Foundation of America, 2019, $100,000
\nHai Rao, PhD[\/vc_column_text][\/vc_column][vc_column width=”1\/3″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column width=”2\/3″][vc_column_text css=””]2026 Development of first-in-class AAK1 Protacs for Ovarian Cancer. R01, 6\/26 \u2013 2\/31, Total Direct Costs: $963,795 Lingtao Jin, PhD Targeting Mucin-Type O-Glycosylation for EGFR mutant non-small cell lung cancer. R01, 4\/26 \u2013 3\/31, Total Direct Costs: $1,036,970 Lingtao Jin, PhD 2025 Targeting Mutant ER-Mediated Enhancer Condensates to Overcome Persistent ER Activity in […]<\/p>\n","protected":false},"author":161,"featured_media":0,"parent":14,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/child-page.php","meta":{"footnotes":""},"class_list":["post-385","page","type-page","status-publish","hentry"],"yoast_head":"\nRecently Awarded Grants | Molecular Medicine | UT Health San Antonio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recently Awarded Grants | Molecular Medicine | UT Health San Antonio\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column width=”2\/3″][vc_column_text css=””]2026 Development of first-in-class AAK1 Protacs for Ovarian Cancer. R01, 6\/26 \u2013 2\/31, Total Direct Costs: $963,795 Lingtao Jin, PhD Targeting Mucin-Type O-Glycosylation for EGFR mutant non-small cell lung cancer. R01, 4\/26 \u2013 3\/31, Total Direct Costs: $1,036,970 Lingtao Jin, PhD 2025 Targeting Mutant ER-Mediated Enhancer Condensates to Overcome Persistent ER Activity in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Molecular Medicine\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T15:07:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/awarded-grants\\\/\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/awarded-grants\\\/\",\"name\":\"Recently Awarded Grants | Molecular Medicine | UT Health San Antonio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/#website\"},\"datePublished\":\"2019-07-11T21:02:25+00:00\",\"dateModified\":\"2026-06-01T15:07:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/awarded-grants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/awarded-grants\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/awarded-grants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Us\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/about\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Awarded Grants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/#website\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/\",\"name\":\"Department of Molecular Medicine\",\"description\":\"Department of Molecular Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/molecular-medicine\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recently Awarded Grants | Molecular Medicine | UT Health San Antonio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/","og_locale":"en_US","og_type":"article","og_title":"Recently Awarded Grants | Molecular Medicine | UT Health San Antonio","og_description":"[vc_row][vc_column width=”2\/3″][vc_column_text css=””]2026 Development of first-in-class AAK1 Protacs for Ovarian Cancer. R01, 6\/26 \u2013 2\/31, Total Direct Costs: $963,795 Lingtao Jin, PhD Targeting Mucin-Type O-Glycosylation for EGFR mutant non-small cell lung cancer. R01, 4\/26 \u2013 3\/31, Total Direct Costs: $1,036,970 Lingtao Jin, PhD 2025 Targeting Mutant ER-Mediated Enhancer Condensates to Overcome Persistent ER Activity in […]","og_url":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/","og_site_name":"Department of Molecular Medicine","article_modified_time":"2026-06-01T15:07:36+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/","url":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/","name":"Recently Awarded Grants | Molecular Medicine | UT Health San Antonio","isPartOf":{"@id":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/#website"},"datePublished":"2019-07-11T21:02:25+00:00","dateModified":"2026-06-01T15:07:36+00:00","breadcrumb":{"@id":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/awarded-grants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/"},{"@type":"ListItem","position":2,"name":"About Us","item":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/about\/"},{"@type":"ListItem","position":3,"name":"Awarded Grants"}]},{"@type":"WebSite","@id":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/#website","url":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/","name":"Department of Molecular Medicine","description":"Department of Molecular Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/pages\/385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/users\/161"}],"replies":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/comments?post=385"}],"version-history":[{"count":1,"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/pages\/385\/revisions"}],"predecessor-version":[{"id":2225,"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/pages\/385\/revisions\/2225"}],"up":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/pages\/14"}],"wp:attachment":[{"href":"https:\/\/lsom.uthscsa.edu\/molecular-medicine\/wp-json\/wp\/v2\/media?parent=385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}